Tracking life quality in men battling advanced prostate cancer

NCT ID NCT06517719

Recruiting now Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study aims to understand how lutetium treatment affects daily life and quality of life in men with advanced prostate cancer that has spread and stopped responding to hormone therapy. Researchers will follow 500 patients receiving this approved treatment in real-world settings, collecting their experiences through questionnaires before, during, and after treatment. The goal is to gather practical information about how patients feel and function while undergoing this therapy.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Novartis Investigative Site
RECRUITING

Konstanz, Baden-Wurttemberg, 78464, Germany
Novartis Investigative Site
RECRUITING

Stuttgart, Baden-Wurttemberg, 70174, Germany
Novartis Investigative Site
RECRUITING

Munich, Bavaria, 81377, Germany
Novartis Investigative Site
RECRUITING

Regensburg, Bavaria, 93053, Germany
Novartis Investigative Site
RECRUITING

Würzburg, Bavaria, 97080, Germany
Novartis Investigative Site
RECRUITING

Cottbus, Brandenburg, 03048, Germany
Novartis Investigative Site
RECRUITING

Frankfurt (Oder), Brandenburg, 15236, Germany
Novartis Investigative Site
RECRUITING

Ludwigshafen, Germany, 67063, Germany
Novartis Investigative Site
RECRUITING

Marburg, Hesse, 35043, Germany
Novartis Investigative Site
RECRUITING

Cologne, North Rhine-Westphalia, 50937, Germany
Novartis Investigative Site
RECRUITING

Dresden, Saxony, 01307, Germany
Novartis Investigative Site
RECRUITING

Leipzig, Saxony, 04103, Germany
Novartis Investigative Site
RECRUITING

Halle, Saxony-Anhalt, 06120, Germany
Novartis Investigative Site
RECRUITING

Jena, Thuringia, 07740, Germany
Novartis Investigative Site
RECRUITING

Aachen, 52074, Germany
Novartis Investigative Site
RECRUITING

Augsburg, 86179, Germany
Novartis Investigative Site
RECRUITING

Berlin, 10249, Germany
Novartis Investigative Site
RECRUITING

Berlin, 12559, Germany
Novartis Investigative Site
RECRUITING

Berlin, 13125, Germany
Novartis Investigative Site
RECRUITING

Bielefeld, 33611, Germany
Novartis Investigative Site
RECRUITING

Bonn, 53105, Germany
Novartis Investigative Site
RECRUITING

Chemnitz, 09113, Germany
Novartis Investigative Site
RECRUITING

Dortmund, 44137, Germany
Novartis Investigative Site
RECRUITING

Dortmund, 44309, Germany
Novartis Investigative Site
RECRUITING

Erlangen, 91054, Germany
Novartis Investigative Site
RECRUITING

Essen, 45147, Germany
Novartis Investigative Site
RECRUITING

Fulda, 36043, Germany
Novartis Investigative Site
RECRUITING

Herford, 32049, Germany
Novartis Investigative Site
RECRUITING

Homburg, 66421, Germany
Novartis Investigative Site
RECRUITING

Magdeburg, 39120, Germany
Novartis Investigative Site
RECRUITING

Mainz, 55131, Germany
Novartis Investigative Site
RECRUITING

Rostock, 18057, Germany
Novartis Investigative Site
RECRUITING

Trier, 54290, Germany
Novartis Investigative Site
RECRUITING

Tübingen, 72076, Germany
Novartis Investigative Site
RECRUITING

Ulm, 89081, Germany

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER